Addiction Medicine - Substances of Abuse Bradley J. Miller, DO

Size: px
Start display at page:

Download "Addiction Medicine - Substances of Abuse Bradley J. Miller, DO"

Transcription

1 Addiction Medicine - Substances of Abuse Bradley J. Miller, DO

2

3 Practical Approaches to Managing Substance Abuse and Nicotine Addiction ACOFP Intensive Update and Board Review in Osteopathic Family Medicine Bradley J. Miller, DO, FAAFP Williamsport Family Medicine Residency Objectives Review current statistics and disease burden of substance abuse in the United States. Describe importance of screening for, provide brief intervention for, and recognize when to refer to treatment for substance abuse disorders in the primary care setting. Review specific substances of abuse (alcohol, nicotine, MJ, opiates) and accepted pharmacologic treatments Question # 1 In patients who die from an opioid overdose, a second substance is often present that contributes to the patient s death. Which one of the following additional substances is most likely to be found in conjunction with a fatal opioid overdose? A) THC (Marijuana) B) Antidepressants C) Cocaine D) Benzodiazepines E) Alcohol 1

4 Current Statistics and Disease Burden 2012 National Survey on Drug Use and Health 23.9 million people over 12 years are current illicit drug users 52.1% of individuals over 12 years report being current drinkers Of all individuals over 12 years who drink 23% binged in the last month 6.5% participate in heavy drinking Current Statistics and Disease Burden 2.1 M ED visits associated with drug misuse or abuse in 53% of all ED visits involved pharmaceuticals Pain relievers- most common Other pharmaceuticals included BZDs alprazolam most reported Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2009: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) , DAWN Series D-35. Rockville, MD: Substance Abuse and Mental Health Services Administration, SAMHSA National Survey Past Month Use of Selected Illicit Drugs among Youths Aged 12 to 17: Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration,

5 SAMHSA National Survey Past Month Nonmedical Use of Types of Psychotherapeutic Drugs among Persons Aged 12 or Older: Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013 Mokdad et al., 2004 SAMHSA National Survey Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration,

6 Top Medications Prescribed 2011 Enough opiate pain medications were prescribed in 2010 to medicate every American adult with 5 mg of hydrocodone taken every 4 hours for an entire MONTH Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, NCHS data brief, no 22. Hyattsville, MD: National Center for Health Statistics Vital Signs: Overdoses of Prescription Opioid Pain Relievers United States, MMWR Volume 60, No. 43. pp November 4, 2011 Death Rates* for Three Selected Causes of Injury National Vital Statistics System, United States, Center for Disease Control, Morbidity and Mortality Weekly, November 21,

7 The Neurochemistry of Addiction Dopamine: Amphetamines, cocaine, alcohol Serotonin: LSD, alcohol Endorphins: Opioids (heroin and narcotics), alcohol GABA: Benzodiazepines, alcohol Glutamate: Alcohol Acetylcholine: Nicotine, alcohol Endocannabinoids: Marijuana, alcohol SCREENING Alcohol What is Low-Risk Drinking?: Females < 7 drinks per week < 3 drinks per occasion Males < 14 drinks per week < 4 drinks per occasion Adults over 65 years of age < 7 drinks per week < 3 drinks per occasion 5

8 Alcohol What constitutes 1 drink?* Beer 12 ounces Shot 1.5 ounces Wine 5 ounces * The definition of a standard drink varies from country to country and study to study; the above is the WHO definition, and is used by the SBIRT initiative What is a standard drink? One 12oz. Can/Bottle of Beer A single shot (1.5 oz.) of distilled spirits (gin, vodka, rum, etc ) A glass of wine (5 oz.) or a small glass of sherry DSM-IV SUD Substance Abuse 1 or more of the following at the same time in a 12-month period: Recurrent use resulting in failure to fulfill major role obligations Recurrent use in situations that are physically hazardous Recurrent legal problems resulting from use Continued use despite having persistent social or interpersonal problems caused or exacerbated by the substance Does not meet criteria for Dependence Substance Dependence 3 or more of the following at the same time in a 12-month period: Tolerance Withdrawal Taken in larger amounts or over longer period than intended Persistent desire or unsuccessful efforts to cut down Great deal of time spent in obtaining, using, and recovering from substance Important activities are given up as a result of substance use Use continues despite knowledge of physical or psychological problem that is caused or exacerbated by the substance 6

9 DSM-V Substance Related Disorders A major overhaul of the DSM-IV criteria for substance use includes the following: Substance Use Disorder (SUD) is a single disorder, measured on a continuum from mild to severe, that combines the DSM-IV abuse and dependence criteria with the following two exceptions: DSM-IV recurrent legal problems has been removed New criterion for craving or a strong desire or urge to use has been added Each specific substance is addressed as a separate use disorder (e.g. alcohol use disorder, opiate use disorder) Cannabis and Caffeine withdrawal are new for DSM-V Gambling disorder has been added DSM-V Substance Use Disorder SUD is accompanied by criteria for intoxication, withdrawal, substance/medication-induced disorders and unspecified substanceinduced disorders. The severity of SUD in DSM-V is based on criteria endorsed: 2-3 mild disorder 4-5 moderate disorder 6 or more severe disorder Helps define SUD as a continuum and removes confusion regarding dependence with addiction when in fact dependence can be a normal body response to a substance Additional modifiers and specifies exist as well. Substance INTOXICATION & WITHDRAWAL are different codes and are dependent on the severity of the SUD National Institute on Alcohol Abuse and Alcoholism NIH Publication No November

10 Question # 2 A 67 year old male with was brought to the emergency department after his friend found him confused at home. The patient typically drinks up to 12 cans of beer daily but has increased over the past 2 months. He has had some falls while intoxicated over the past year and has tried to cut down but hasn t been able to do so. His family has been encouraging him to cut down and he has been unsuccessful. He decided to stop drinking and his last drink was about 20 hours ago. When found, the patient referred to his friend as his wife who has been deceased for 2 years. Which of the following is most accurate? (A) The patient meets diagnostic criteria for moderate alcohol use disorder and is beginning to have delirium tremens (B) The patient meets diagnostic criteria severe alcohol use disorder and is beginning to have delirium tremens (C)The patient meets diagnostic criteria for moderate to severe alcohol use disorder and is beginning to have alcohol hallucinations (D) Naltrexone, thiamine and folate should be given to the patient prior to treatment with lorazepam (E) None of the above Alcohol Alcohol Withdrawal Syndromes Pathophysiology of ETOH withdrawal Abrupt withdrawal unmasks compensatory over-activity of the nervous system. Alters levels of GABA, Norepinephrine and Serotonin Minor Withdrawal Symptoms Due to CNS and sympathetic hyperactivity Usually present within 6 hrs of drinking cessation Insomnia, tremulousness, anxiety, GI upset, HA, diphoresis, palpitations, or anorexia Resolve within hours consistent from one episode to the next 8

11 Alcohol Withdrawal Syndromes Withdrawal Seizures Usually tonic-clinic convulsions within 48 hours of last drink 3% of chronic alcoholics have withdrawal seizures of which 3% develop status epilepticus Usually a singe episode. Recurrent or prolonged seizures require investigation of another source Alcohol Withdrawal Syndromes Alcoholic Hallucinations Often mistaken for delirium tremens (DTs) Hallucinations that develop hrs from abstinence and resolve within hrs (which is when DTs typically begin) Usually visual but can be auditory and tactile Usually associated with specific hallucinations and not global clouding of the sensorium (as with DTs) Alcohol Withdrawal Syndromes Delirium Tremens Occurs in 5% of pts experiencing withdrawal Hallucinations, disorientation, tachycardia, HTN, low grade fever, agitation, and diaphoresis. Typically begin between 48 & 72 hrs and last one to five days Mortality rate of 5% death usually from arrhythmias or complicating illnesses such as pneumonia 9

12 Treatment Inpatient vs outpatient For all patients: 1. Thiamine 100mg oral/iv daily (before glucose containing fluids to avoid Wernicke encephalopathy) 2. Folate 1 mg oral for 3 days Outpatient Pharmacotherapy for ETOH Dependence Three agents approved by FDA for adjunctive therapy for the treatment of alcohol dependence (other agents exist) Naltrexone Pure opioid receptor antagonist Blunts pleasurable effects of alcohol and reduces cravings Reduces relapse and number of drinking days CAUTION: Will cause opiate withdrawal! BLACK BOX WARNING-acute hepatic toxicity Naltrexone PO (ReVia ) / IM Depot (Vivitrol ) Typical starting and maintenance oral dose is 50mg daily High risk patients should start at 12.5mg or 25mg and titrate up OR 380mg IM q 4 weeks 10

13 Outpatient Pharmacotherapy for ETOH dependence Acamprosate (Campral) Structural analog of GABA Decreases excitatory glutameric neurotransmission during withdrawal 666 mg TID. May need to adjust if pt has diarrhea Disulfiram (Antabuse) Deterrent- causes flushing, nausea, vomiting, tachycardia, dyspnea, HA, blurred vision, vertigo and anxiety minutes after ingestion of ETOH Indications for inpatient alcohol detoxification Indications for inpatient alcohol detoxification - History of severe withdrawal symptoms - History of alcohol withdrawal seizures or DTs - Multiple past detoxifications - Other medical or psychiatric illness - Recent high levels of alcohol consumption - Lack of reliable support network - Pregnancy Myrick,H. Treatment of alcohol withdrawal. Alcohol Health and Research World, 1998, Vol.22 Issue 1, Treatment Gradual Tapering Regimen - predetermined dosing schedule for several days as the medication is gradually discontinued (mostly used outpatient) 11

14 Treatment One of the following: 1. Chlordiazepoxide (Librium ) mg every 6 hours for 4 doses then mg every 6 hours for 8 doses 2. Diazepam (Valium ) 10-20mg every 6 hours for 4 doses then 5-10mg every 6 hours for 8 doses 3. Lorazepam (Ativan ) 2-4 mg every 6 hours for 4 doses then 1-2 mg every 8 hours for 8 doses (medication of choice with hepatic dysfunction) 4. Carbamazepine (Tegretol ) 200 mg QID x 1 day 200 mg TID x 1 day 200 mg BID x 1 day 200 mg BID x 1 day 200 mg daily x 2 days Asplund.C. Three regimens for alcohol withdrawal and detoxification. The Journal of Family Practice. July Vol. 53. Treatment Fixed Schedule Regimen 1. Diazepam (Valium ) Dose: mg PO q1h prn while awake Endpoint: until adequate Sedation 2. Lorazepam (Ativan ) Dose: 1-2 mg IV q1h prn while awake for 3-5 days Endpoint: until adequate Sedation 3. Chlordiazepoxide (Librium ) Dose: 50 to 100 mg PO/IM/IV q4h (max: 300 mg/day) Endpoint: until adequate Sedation Associated with overmedication Moses,S. Alcohol Withdrawal. Treatment Symptom-Triggered Regimen - Pt withdrawal score is determined hourly or bihourly and the medication is administered only when the score is elevated >8 on clinical withdrawal scale 12

15 Treatment Clinical Institute Withdrawal Assessment Revised Scale (CIW-Ar) <10: Very mild withdrawal 10-15: Mild withdrawal 16-20: Modest withdrawal >20: Severe withdrawal Smith,M. Management of alcohol intoxication and withdrawal. Principles of Addiction Medicine. 4th edition Additional Interventions Phenobarbital or propofol for refractory DTs May require mechanical ventilation and ICU admission Phenothiazines and butyrophenones (including Haldol) AVOID- lower seizure threshold Anticonvulsants- controversial if effective. Most seizures are self limited and do not require medication Consider phenytoin Question # 3 The five A s Model for treating tobacco abuse and dependence include all of the following except A Ask about tobacco use on every patient B Advise to quit C Assess willingness to made a quit attempt D Assist in the quit attempt E Arrange for nicotine support group 13

16 Nicotine Nicotine Tobacco is the chief avoidable cause of illness and death in our society Accounts for more than 435,000 deaths/yr 45 million smokers in the United States 70% of them want to quit 20 million attempt to quit each year, unaided only 4-7% are successful Dependence among users Difficulty achieving abstinence nicotine>heroin>cocaine>alcohol>caffeine (alcohol=cocaine=heroin=nicotine)>caffeine Tolerance (alcohol=heroin=nicotine)>cocaine>caffeine Physical alcohol>heroin>nicotine>cocaine>caffeine withdrawal severity Deaths Importance in user's daily life Prevalence nicotine>alcohol>(cocaine=heroin)>caffeine (alcohol=cocaine=heroin=nicotine)>caffeine caffeine>nicotine>alcohol>(cocaine=heroin) 14

17 The 5 A's Model for Treating Tobacco Use and Dependence Ask about tobacco on every patient Advise to quit. Assess willingness to make a quit attempt. Assist in quit attempt Arrange follow up First-Line Medications Nicotine Replacement Therapy (NRT) -Patch (OTC) -Gum (OTC) -Lozenge (OTC) -Oral Inhaler (Rx) -Nasal Spray (Rx) Non-Nicotine Medications -Varenicline (Chantix, Rx) -Bupropion Hydrochloride (Rx) NRT Medications Use high enough dose Scheduled dosing better than PRN Can be combined with Bupropion Don t combine with Varenicline Can be combined with each other Have very few contraindications Have no drug-drug interactions 15

18 Dosing: < 10 cigs/day: 14 mg patch 10 cigs/day: 21 mg patch Length of Treatment: -Up to 12 weeks Pros: -Easy, good compliance -Continuous nicotine delivery -OTC Cons: -Slow onset of action -Skin reaction -Insomnia Nicotine Patch Dosing: 2mg < 25 cigarettes/day 4mg > 25 cigarettes/day Length of Treatment: 8-10 weeks Nicotine Gum Use: - Chew and park (Slow, buccal absorption) - Acidic foods absorption Pros: -Flexible dosing (every 1-2 hours, up to 24 pieces/day) -Keeps mouth busy -OTC Cons: -Need to use correctly (chew and park) -Nausea, Heartburn Mouth and throat burning Nicotine Lozenge Dosing: Based on Time To First Cigarette (TTFC) 4 mg if 30 mins TTFC 2mg > if 30 mins TTFC Length of Treatment: 12 weeks Use: -Allow to dissolve (Don t Chew but Suck like a hard candy.) Pros: -Flexible dosing (Up to 20 lozenges/ day) More discreet than gum -Keep mouth busy -OTC Cons: Need to use correctly (don t chew, suck) May cause insomnia, some nausea, hiccups, heartburn, coughing 16

19 Nicotine Nasal Spray Dosing: 1-2 doses per hour 1 does = 2 spays (1 spray/nostril) Use enough to control withdrawal symptoms Length of Treatment: 3-6 months weeks (PDR) Use: -Spray (don t sniff, swallow, or inhale) -PRN or fixed-schedule (1-2 doses/hour) Pros: -Rapid delivery though nasal mucosa -Flexible dosing (up to 40 doses) Cons: -Nasal irritation, rhinitis, coughing, & watering eyes. -Rx needed Non-Nicotine Pharmacotherapy First-line non-nrt medications FDA approved -Bupropion (Zyban/Wellbutrin) -Varenicline (Chantix) Others (nortriptyline, clonidine) Bupropion Hydrochloride Dopamine and norepinephrine (noradrenaline) effects Reduces cravings, withdrawal Improved abstinence rates in trials Less weight gain while using Start 7-10 days prior to quit date Continue 7-12 weeks or longer ( > 6 months) 17

20 Bupropion Precautions Contraindicated: seizure disorder, eating disorders, electrolyte abnormalities, MAO use OK with SSRIs NOT dangerous to smoke while taking Monitor blood pressure Side effects: Insomnia (40%) Dry mouth Headaches Rash Varenicline (Chantix) Action at 4 2 nicotine receptor Partial agonist/antagonist Releases lower amounts of dopamine into brain than smoke Reduces withdrawal Not as addictive as smoke Blocks nicotine from binding to receptor Prevents reward of smoking Varenicline (Chantix) In 2008 FDA added a warning regarding the use of varenicline noting that depressed mood, agitation, changes in behavior, suicidal ideation, & suicide have been reported in patients attempting to quit smoking while using varenicline. FDA recommends that: 1. Patients tell their healthcare provider about any history of psychiatric illness prior to starting this medication 2. Clinicians monitor patients for changes in mood and behavior when prescribing this medication 18

21 Electronic Cigarettes Introduced into US in 2007 Use has tripled among teens from No FDA regulations (yet) Can be purchased online No age restrictions Solvents used to dissolve nicotine are irritants and may be carcinogenic Companies don t disclose all ingredients of their electronic cigarette Electronic Cigarettes E-cigs vs. placebo helped with abstinence from smoking traditional cigs 30 days or less but not long term Surpasses all other forms of tobacco in youth population Flavors that might appeal to younger age group (chocolate, bubble gum ) Question # 4 Which of the following is the most commonly abused illicit drug in the US? A lorazepam B cannabinoids (marijuana) C opiates (heroin and pain medication) D alcohol E cocaine 19

22 Marijuana Marijuana Marijuana is the most commonly abused illicit drug in the United States Long-term marijuana abuse can lead to addiction; compulsive drug seeking and abuse despite its known harmful effects upon social functioning Long-term marijuana abusers trying to quit report irritability, sleeplessness, decreased appetite, anxiety, and drug craving, all of which make it difficult to quit Effect on Mental Health: Causes increased rates of anxiety, depress, SI, and schizophrenia. National Institute on Drug Abuse (NIDA) Website; Question # 5 An intoxicated patient is brought to the emergency department. Ocular examination reveals miosis. This patient was most likely using which of the following substances? (A) alcohol (B) cocaine (C) opioids (D) PCP (E) sedatives 20

23 Opiates Opiate Addiction Pharmacologic Interventions Opiate Agonists Methadone Partial Agonist, Partial agonist/antagonist buprenorphine buprenorphine/naloxone Antagonist Naltrexone (Vivtrol ) Why are opioid medications used to treat opioid addictions? Common myth is that all medications used to treat addictions are simply substituting one addiction for another Research has found that addiction to opioids results in significant changes in brain chemistry and function. Some of these changes may be permanent, meaning some individuals may require an opiate to bind to their changed receptors in order to function normally. Medication therapy significantly helps individuals stay in treatment more consistently, stay healthier, stay out of legal trouble, and generally function well in society. 21

24 Naltrexone (Vivitrol ) Naltrexone is a opiate antagonist Tightly blocks mu opioid receptors FDA approved for treating alcohol dependence and opiate dependence Decreases cravings in patients who abuse alcohol Comes in oral and IM depot formulations oral used to trial naltrexone prior to committing to IM IM- (Vivitrol ) depot formulation that is given monthly. If patients use opiates while on, no high. CAUTION: Will cause opiate withdrawal BLACK BOX WARNING-acute hepatic toxicity What is buprenorphine? Buprenorphine is a partial agonist of the mu opioid receptor Binds to and activates the receptor Partial agonists have a ceiling effect: larger doses do not produce greater highs-- has a very low risk of abuse and overdose. How does being a partial agonist safeguard against abuse? Features of Suboxone include: buprenorphine mixed with the antagonist naloxone (not in pregnancy) It must be taken correctly (dissolved under the tongue) to work correctly. If injected, the naloxone will bind to the receptors and put the person into rapid withdrawal. If it is swallowed without dissolving, there is no effect. When taken correctly, will act as an agonist and reduce craving and withdrawal symptoms. Once ceiling effect is achieved, other opioids such as heroin, are not able to bind to the receptors and therefore will produce no effects. If administered while using other opiates, it may act as an antagonist and put the person into immediate withdrawal. 22

25 References Creating Opportunities for Reducing Alcohol Related Harm in the Veteran Community; Session 6: Brief Intervention. Version 2.3. Department of Veterans Affairs, Australia. December 2002 < Thomas Babor, John Higgins-Biddle. Brief Intervention for Hazardous and Harmful Drinking-A Manual for Use in Primary Care. World Health Organization, Department of Mental Health and Substance Dependence Gentilello et al. Alcohol Interventions in a Trauma Center as a Means of Reducing Risk of Injury Recurrence. Annals Surgery 1999;230: National Survey on Drug Use and Health (NSDUH) sponsored by the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies (OAS). National Institute on Drug Abuse (NIDA) Website; Gold, MS and Aronson, MD. Treatment of Alcohol Use and Dependence. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, Weinhouse, GL. Alcohol Withdrawal Syndromes. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, Motivational Interviewing: Resources for clinicians, researchers and trainers. Interaction Techniques. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May American Academy of Family Physicians. Studies Suggest E-Cigarettes Don't Aid Long-term Smoking Cessation: American Family Physician. June

Addiction Medicine Substances of Abuse Bradley J. Miller, DO

Addiction Medicine Substances of Abuse Bradley J. Miller, DO Addiction Medicine Substances of Abuse Bradley J. Miller, DO Practical Approaches to Managing Substance Abuse and Nicotine Addiction ACOFP Intensive Update and Board Review in Osteopathic Family Medicine

More information

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over

More information

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days

More information

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.

5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated. 0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,

More information

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?

More information

Please review the following slides prior to class. Information from these slides will be used to answer patient cases. Come prepared!

Please review the following slides prior to class. Information from these slides will be used to answer patient cases. Come prepared! Please review the following slides prior to class Information from these slides will be used to answer patient cases. Come prepared! Alcohol and Opiate Dependence Reference Slides Substances of Abuse A

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

THE STATE OF MEDICINE IN ADDICTION RECOVERY

THE STATE OF MEDICINE IN ADDICTION RECOVERY OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,

More information

Pharmacotherapy for Treating Tobacco Dependence

Pharmacotherapy for Treating Tobacco Dependence Pharmacotherapy for Treating Tobacco Dependence Sheila K. Stevens, MSW Education Coordinator Nicotine Dependence Center 2013 MFMER slide-1 Rationale for Pharmacological Therapy Success rate doubles Manage

More information

Addiction Medicine: What s new for primary care

Addiction Medicine: What s new for primary care Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in

More information

Dr. Renner receives honoraria from Reed Medical Education

Dr. Renner receives honoraria from Reed Medical Education Substance Use Disorders Symposium on Men s Health Massachusetts Medical Society June 17, 2010 John A. Renner, Jr., M.D. John A. Renner Jr., MD DISCLOSURES Johnson & Johnson Stock Holder Dr. Renner receives

More information

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Biological Addictions Treatment. Psychology 470. Many Types of Approaches Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches

More information

SMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.

SMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami. SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd

More information

Medication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019

Medication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools

More information

Hot Topics in Addiction Medicine. Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017

Hot Topics in Addiction Medicine. Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017 Hot Topics in Addiction Medicine Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017 Financial Disclosures Speaker Bureau Indivior Research Support Constellation Health Onward Hot Topics

More information

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.

More information

Pharmacologic Interventions for. Addictions

Pharmacologic Interventions for. Addictions Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.

More information

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History

More information

Smoking Cessation: Treating Tobacco Dependence

Smoking Cessation: Treating Tobacco Dependence Smoking Cessation: Treating Tobacco Dependence Pat Folan, RN Center for Tobacco Control Pulmonary Medicine NS-LIJ Health System NYS DOH Tobacco Control Program Treating Tobacco Dependence Center for Tobacco

More information

EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO

EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization

More information

Effective Treatments for Tobacco Dependence

Effective Treatments for Tobacco Dependence Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for

More information

Substance Use Disorders

Substance Use Disorders Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and

More information

Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1

Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1 Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1 Compiled by: TOP, in collaboration with Dr. Charl Els and Mr. Ron Pohar: TRaC II (Alberta Medical Association/Primary

More information

Withdrawal.

Withdrawal. Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts General

More information

PHARMACOTHERAPY OF SMOKING CESSATION

PHARMACOTHERAPY OF SMOKING CESSATION PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure

More information

Treatment Team Approaches in Substance Abuse Treatment

Treatment Team Approaches in Substance Abuse Treatment Treatment Team Approaches in Substance Abuse Treatment PLANT A SEED AND WATCH IT GROW 2 Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:

More information

IMPORTANT POINTS ABOUT MEDICATIONS

IMPORTANT POINTS ABOUT MEDICATIONS IMPORTANT POINTS ABOUT MEDICATIONS The U.S. Food & Drug Administration (FDA) advises that there are significant health benefits to quitting smoking. The health benefits of quitting smoking include a reduction

More information

My Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.

My Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon. My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,

More information

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING

More information

Tobacco & Nicotine: Addiction and Treatment

Tobacco & Nicotine: Addiction and Treatment Tobacco & Nicotine: Addiction and Treatment Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University of Washington, School

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Medication for the Treatment of Alcohol Use Disorder. Pocket Guide

Medication for the Treatment of Alcohol Use Disorder. Pocket Guide Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated

More information

MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS

MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS PHYLLIS RAYNOR, PHD, PMHNP-BC, APRN CLINICAL ASSISTANT PROFESSOR, USC COLLEGE OF NURSING LEARNING OBJECTIVES: Define types of SUD and purposes

More information

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS Ending Addiction Changes Everything RECOMMENDATIONS FOR HEALTH CARE PROVIDERS CRITICAL ADDICTION PREVENTION, TREATMENT AND MANAGEMENT SERVICES TO INCLUDE IN ROUTINE HEALTH CARE PRACTICE JULY 2013 In the

More information

HIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA

HIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA HIV and Aging Making Tobacco Cessation a Priority in HIV/AIDS Services June 27, 2008 Amanda Brown, MPH Ruth Tripp, MPH, RN Objectives To explore existing knowledge of the HIV and smoking connection. To

More information

Smoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service

Smoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service Smoke-free Hospitals Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service Today s Subjects 5A s and Clinician Training and Use with the Hospitalized Patient NRT use in

More information

Nicotine Replacement Therapy, Zyban and Champix. Name of presentation

Nicotine Replacement Therapy, Zyban and Champix. Name of presentation Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit

More information

Smoking cessation therapy

Smoking cessation therapy Appendix 1 Smoking cessation therapy Q. Can a dentist prescribe medications for smoking cessation? A. Yes. Dentists are allowed and are encouraged to help patients with smoking cessation by counseling

More information

Pharmacologic Therapy for Tobacco Use & Dependence

Pharmacologic Therapy for Tobacco Use & Dependence Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

Nicotine Replacement and Smoking Cessation: Update on Best Practices

Nicotine Replacement and Smoking Cessation: Update on Best Practices Nicotine Replacement and Smoking Cessation: Update on Best Practices Adrienne Duckworth, MSN, APRN, FNP-C, CTTS Section of Hematology/Oncology WVU Department of Medicine WVU Cancer Institute Objective

More information

Smoking Cessation: Where Are We Now? Nancy Rigotti, MD

Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Complicated Withdrawal

Complicated Withdrawal Complicated Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts

More information

DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS

DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS MAJOR CATEGORIES OF TREATMENTS Detoxification and Post-Acute Withdrawal Maintenance Co-Occurring

More information

Pharmacotherapy for Substance Use Disorders

Pharmacotherapy for Substance Use Disorders Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,

More information

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 1 Expanded to include Gambling Disorder Cannabis Withdrawal and Caffeine Withdrawal are new disorders Caffeine Withdrawal

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

TREATMENT INTERVENTIONS

TREATMENT INTERVENTIONS SMOKING CESSATION TREATMENT INTERVENTIONS Smoking and Health Tobacco is the single most preventable cause of death in the world today. kills more than five million people By 2030, the death toll will exceed

More information

Treatment of Alcohol and Opiate Withdrawal

Treatment of Alcohol and Opiate Withdrawal Objectives Treatment of Alcohol and Opiate Withdrawal Renee Striker, Pharm.D., BCPS, BCPP Pharmacy Clinical Specialist Huron Hospital East Cleveland, Ohio Outline the diagnostic criteria for substance

More information

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 % Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Complicated Withdrawal

Complicated Withdrawal Complicated Withdrawal Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@Swedish.org Disclosures: Shamim Nejad,

More information

Polysubstance Use & Medication-Assisted Treatment

Polysubstance Use & Medication-Assisted Treatment Polysubstance Use & Medication-Assisted Treatment DSM-V eliminated polysubstance disorder, instead specifying each drug of abuse and dependence. Substance-use disorder is a combination of the two DSM-IV

More information

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01

More information

Addressing Tobacco Use in Iowa

Addressing Tobacco Use in Iowa Addressing Tobacco Use in Iowa A BRIEF TOBACCO INTERVENTION FOR HEALTHCARE PROVIDERS Lorene Mein Beth Turner Alyssa Reichelt DNP, ARNP, FNP-BC MA, CHES MA Mercy Clinics American Lung Association American

More information

Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.

Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty

More information

NIDA-Modified ASSIST Prescreen V1.0 1

NIDA-Modified ASSIST Prescreen V1.0 1 NIDA-Modified ASSIST Prescreen V1.0 1 F Name:... Sex ( ) F ( ) M Age... Interviewer... Date.../.../... Introduction (Please read to patient) Hi, I m, nice to meet you. If it s okay with you, I d like to

More information

Medication for Addiction Treatment (MAT)

Medication for Addiction Treatment (MAT) SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health

More information

Tobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing

Tobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing

More information

Outpatient Tobacco Addiction Treatment Pathway Additional Notes

Outpatient Tobacco Addiction Treatment Pathway Additional Notes Outpatient Tobacco Addiction Treatment Pathway Additional Notes First Line: Varenicline (provide in conjunction with counselling/support, but if such support is refused or is not available, this should

More information

Treating Tobacco Use:

Treating Tobacco Use: Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

NIDA-Modified ASSIST - Prescreen V1.0*

NIDA-Modified ASSIST - Prescreen V1.0* NIDA-Modified ASSIST Assessment Instrument [1] NIDA-Modified ASSIST - Prescreen V1.0* *This screening tool was adapted from the WHO Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) Version

More information

Common Diagnosis Codes and Tips for Coding Nicotine Use/

Common Diagnosis Codes and Tips for Coding Nicotine Use/ ICD-10 Tobacco Billing Guide ICD-10 and Tobacco Common Diagnosis Codes and Tips for Coding Nicotine Use/ Dependence Tobacco use is the leading cause of preventable disease and death in the United States,

More information

SMOKING CESSATION IS HARD

SMOKING CESSATION IS HARD POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping

More information

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening

More information

Helping People Quit Tobacco

Helping People Quit Tobacco Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research

More information

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS

C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS 1.0 Introduction Medications are used in the treatment of drug, alcohol and nicotine dependence to manage

More information

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH THERAPEUTIC INTERVENTION AND RESOURCE MANAGEMENT: SUBSTANCE RELATED DISORDERS: CO-DEPENDENCY AND THE IMPAIRED NURSE LECTURE OBJECTIVES:

More information

Over the Road Truck Driver Who Smokes

Over the Road Truck Driver Who Smokes Continuing Medical Education Case Presentation 1 CME Credit Physicians Physician Assistants Nurse Practitioners Over the Road Truck Driver Who Smokes RELEASE & REVIEW DATE This activity was last reviewed

More information

Brief Intervention for Smoking Cessation. National Training Programme

Brief Intervention for Smoking Cessation. National Training Programme Brief Intervention for Smoking Cessation National Training Programme Introduction Monitor tobacco use and prevention policies Protect people from tobacco smoke Offer help to quit tobacco use Warn about

More information

Pharmacotherapy for Tobacco Dependence Treatment

Pharmacotherapy for Tobacco Dependence Treatment Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org

More information

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today

More information

Complicated Withdrawal

Complicated Withdrawal Complicated Withdrawal Shamim Nejad, MD Medical Director, Division of Psychosocial Oncology Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@Swedish.org Disclosures: Shamim

More information

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Basics of Benzodiazepine Use Disorder DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members

More information

Wanting to Get Pregnant

Wanting to Get Pregnant Continuing Medical Education COPD Case Presentation LEARNING OBJECTIVES Those completing this activity will receive information that should allow them to Assist a patient in developing a quit plan; Advise

More information

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation

More information

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA Managing Patients with Substance Abuse Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA Objectives Epidemiology: Substances most likely to be misused in HIV care settings. Diagnostic and

More information

Drug abuse: Drug misuse Dependence abuse

Drug abuse: Drug misuse Dependence abuse Drug abuse: Use of drugs for non-medical purposes Drug misuse: wrong use of drugs: Wrong choice Wrong dose & wrong duration e.g. misuse of antibiotics Dependence is associated with abuse 1 Repeated, periodic

More information

3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine

3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive

More information

Alcoholism has been demonstrated to have a genetic component, especially among men.

Alcoholism has been demonstrated to have a genetic component, especially among men. Causes and Treatment of Substance-Related Disorders (Chapter 10) Familial and Genetic Influences Alcoholism has been demonstrated to have a genetic component, especially among men. Seems to be a common

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Serious Mental Illness and Opioid Use Disorder

Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,

More information

1/10/2017. A common Alcoholics Anonymous (AA) saying is There is no problem that alcohol cannot make worse.

1/10/2017. A common Alcoholics Anonymous (AA) saying is There is no problem that alcohol cannot make worse. Alcohol still addicts more people than all other drugs combined Understand difference between alcohol use, abuse and dependence Learn the potential physiological and emotional affects of alcohol Distinguish

More information

NIDA Quick Screen V1.0F1

NIDA Quick Screen V1.0F1 NIDA Quick Screen V1.0F1 Name:... Sex ( ) F ( ) M Age... Interviewer... Date.../.../... Introduction (Please read to patient) Hi, I m, nice to meet you. If it s okay with you, I d like to ask you a few

More information

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol

More information

Varenicline and Other Pharmacotherapies for Tobacco Dependence

Varenicline and Other Pharmacotherapies for Tobacco Dependence Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism

More information

Appendix F Federation of State Medical Boards

Appendix F Federation of State Medical Boards Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction

More information

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS

TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Learning Objectives TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of

More information

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation

More information

H NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher.

H NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher. H NDS-ONHealth Health Wave Newsletter, October 2013 Visit us on our website at www.healthwaveinc.com Drug overdose death rates in the United States have more than tripled since 1990 and have never been

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions

Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures

More information

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic

More information

1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation

1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms

More information